Navigation Links
PUR Biologics’ Novel Orthopedic Developments Supported by Two New US Patents

Irvine, CA (PRWEB) September 10, 2013

PUR Biologics, LLC, a joint venture focused on the emerging field of biologics for musculoskeletal conditions, including spine, dental and medical device applications, today announced that the United States Patent & Trademark Office has issued two patents covering the multipotent stem cell-derived material utilized by PUR, and its applications in the repair and regeneration of tissue.

The US Patent & Trademark Office issued patent 8,524,494, entitled “Low Oxygen Tension and bFGF Generates a Multipotent Stem Cell from a Fibroblast In Vitro”, and patent 8,530,415, entitled “Repair and/or Regeneration of Cells with a Composition Produced by Culturing Fibroblast Cells under Hypoxic Conditions”, to PUR’s joint venture partner, Histogen, Inc., on September 3 and September 9, 2013, respectively.

The issued patents cover Histogen’s novel technology which triggers the de-differentiation of fibroblast cells into multipotent stem cells through low oxygen and special culture conditions, as well as methods of inducing tissue repair and regeneration by contacting cells with the naturally-secreted multipotent cell conditioned media (CCM) and extracellular matrix (ECM) materials.

“These novel multipotent cell-derived materials hold tremendous potential in orthopedic applications, where we seek to regenerate musculoskeletal tissues and support stem cell growth,” said Ryan Fernan, CEO of PUR Biologics. “Particularly exciting to us is the ability of the material to induce angiogenesis, which is not addressed with currently available orthopedic products.”

Unlike other stem cell-derived therapies, Histogen’s process uniquely begins with newborn fibroblast cells, a safe, well-established and non-controversial cell source, and converts the cells into multipotent stem cells without genetic manipulation. PUR Biologics is currently researching and developing products based upon the CCM and ECM materials produced by these multipotent cells, which have potential benefit in a number of orthopedic applications such as bone and cartilage regeneration.

“While there is a lot of excitement and promise around stem cell-derived treatments in orthopedics, therapies utilizing embryonic stem cells or genetically-manipulated induced pluripotent stem cells carry inherent ethical and potential safety concerns for patients,” said Dr. Burak Ozgur, Chief of Neurosurgery Spine Service at Hoag Hospital. “Products that could capture the benefits of stem cell treatments without these concerns, such as the multipotent cell materials being developed by PUR, hold tremendous potential as the future of orthopedics.”

About PUR Biologics
PUR Biologics is dedicated to providing regenerative biologic solutions to address musculoskeletal surgical needs, including spine, dental, ligament and medical device coating applications. In addition to distribution of approved allograft and biologic products, PUR is focused on development of next-generation orthopedic products based upon human protein and growth factor materials for bone and tissue regeneration. For more information visit

About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen's technology focuses on stimulating a patient's own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Study Published in Nature Biotechnology Demonstrates Ability of Modernas Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
2. Novel topological crystalline insulator shows mass appeal
3. Novelda Appoints Alf-Egil Bogen as Chief Executive Officer to Lead the Company to the Next Level
4. Medasense Receives Patent Approval for Novel Pain-Monitoring System
5. Micropharma Limited announces new agreement to commercialize novel natural health products
6. Pure Transplant Solutions Launches Crowdfunding Campaign for Its Novel Technology Poised to Change the Future of Organ Transplantation
7. Further Evidence that the PhotoActivation of PRP (PAPRP) is a Novel and Effective Treatment for Osteoarthritis and Knee Pain
8. Novel study using new technologies outlines importance of California condor social groups
9. Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies
10. NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI
11. Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing”
Post Your Comments:
(Date:11/25/2015)... , November 26, 2015 ... Biobanking Market 2016 - 2020 report analyzes that ... integrity and quality in long-term samples, minimizing manual ... cost-effectiveness. Automation minimizes manual errors such as mislabeling ... efficiency. Further, it plays a vital role in ...
(Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... 25, 2015 The Global ... a professional and in-depth study on the current ... (Logo: ) , The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):